Pennsylvania Sued Insulin Makers and Benefit Managers
The state attorney general alleges a conspiracy to inflate insulin costs by over 1,000 percent.
Updated on Oct. 13, 2026 in Diabetes
Live Poll
Should pharmaceutical companies and pharmacy benefit managers face legal action over rising insulin prices?
Pennsylvania Attorney General Dave Sunday has filed a lawsuit against major insulin manufacturers and pharmacy benefit managers. The complaint claims these companies conspired to manipulate price markets, leading to significantly higher out-of-pocket costs for patients.
Why it matters
The legal action seeks to address allegations that corporate pricing strategies have created financial barriers to essential life-saving medication. By targeting both manufacturers and managers, the state aims to uncover the mechanisms driving excessive insulin costs.
The lawsuit cites an alleged price inflation of over 1,000 percent compared to historical baseline costs. Investigators are currently determining the full extent of the financial damages incurred by Pennsylvania residents.
The players
Dave Sunday
He is the Attorney General of Pennsylvania who is leading the state's legal challenge against pharmaceutical and benefit management companies.
Eli Lilly and Co.
It is a global pharmaceutical corporation named as a defendant in the Pennsylvania lawsuit.
Novo Nordisk
It is a multinational pharmaceutical firm and a named defendant in the price manipulation lawsuit.
Sanofi-Aventis US
It is a major manufacturer of insulin and one of the companies sued by the state of Pennsylvania.
CVS Caremark
It is a pharmacy benefit manager named in the complaint for its alleged role in market manipulation.
The details
The complaint names Eli Lilly and Co., Novo Nordisk, and Sanofi-Aventis US as manufacturing defendants, alongside pharmacy benefit managers Express Scripts, CVS Caremark, and Optum RX. The lawsuit alleges that these entities conspired to manipulate the insulin market, directly resulting in increased expenses for consumers.
Timeline
The lawsuit regarding insulin prices was officially announced on October 13, 2026.
Health Landscape
This lawsuit extends the legal efforts to ensure medication affordability previously supported by the Affordable Care Act's patient protection provisions.
The lawsuit could eventually influence the out-of-pocket costs that Pennsylvania residents pay for insulin at the pharmacy counter. Patients should continue to work with their healthcare providers regarding their current treatment plans and insurance coverage.
The takeaway
Patients should monitor their monthly medical expenses and discuss any financial assistance programs directly with their pharmacy. Understanding the impact of pharmacy benefit managers on drug prices is essential for navigating modern healthcare costs.
Further reading
Learn more about local efforts to manage health costs on the Pennsylvania Diabetes page.
Source note: This article includes information reported by Mlex.
Live Poll
Should pharmaceutical companies and pharmacy benefit managers face legal action over rising insulin prices?
